Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 217

1.

Current approaches to anticoagulation for reducing risk of atrial fibrillation-related stroke.

Sanoski CA.

J Pharm Pract. 2013 Jun;26(3):204-13. doi: 10.1177/0897190012452309. Epub 2012 Jul 25.

PMID:
22842506
2.

The costs of warfarin underuse and nonadherence in patients with atrial fibrillation: a commercial insurer perspective.

Casciano JP, Dotiwala ZJ, Martin BC, Kwong WJ.

J Manag Care Pharm. 2013 May;19(4):302-16.

3.

Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.

Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY.

Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7. Review.

PMID:
22684583
4.

The hidden costs of anticoagulation in hospitalized patients with non-valvular atrial fibrillation.

Burnett A, Tiongson J, Downey R, Mahan CE.

Expert Opin Pharmacother. 2013 Jun;14(9):1119-33. doi: 10.1517/14656566.2013.789022. Epub 2013 Apr 11. Review.

PMID:
23574619
5.

An update on antithrombotic therapy in atrial fibrillation: the role of newer and emergent drugs.

Deedwania P, Huang GW.

Rev Cardiovasc Med. 2012;13(2-3):e89-104. Review.

PMID:
23160166
6.
7.

Anticoagulation influences long-term outcome in patients with nonvalvular atrial fibrillation and severe ischemic stroke.

Vemmos KN, Tsivgoulis G, Spengos K, Manios E, Toumanidis S, Zakopoulos N, Moulopoulos SD.

Am J Geriatr Pharmacother. 2004 Dec;2(4):265-73.

PMID:
15903285
8.

Effective anticoagulation therapy: defining the gap between clinical studies and clinical practice.

Wittkowsky AK.

Am J Manag Care. 2004 Oct;10(10 Suppl):S297-306; discussion S312-7. Review.

9.

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation--a real patient data analysis in a Hong Kong teaching hospital.

Chang AM, Ho JC, Yan BP, Yu CM, Lam YY, Lee VW.

Clin Cardiol. 2013 May;36(5):280-5. doi: 10.1002/clc.22112. Epub 2013 Mar 14.

10.

Preventing stroke in atrial fibrillation: the SPORTIF programme.

Lip GY.

Pathophysiol Haemost Thromb. 2005;34 Suppl 1:25-30. Review.

PMID:
15812201
11.
12.

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.

Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP.

Ann Intern Med. 2011 Jan 4;154(1):1-11. doi: 10.7326/0003-4819-154-1-201101040-00289. Epub 2010 Nov 1.

PMID:
21041570
13.

Review of economics and cost-effectiveness analyses of anticoagulant therapy for stroke prevention in atrial fibrillation in the US.

von Schéele B, Fernandez M, Hogue SL, Kwong WJ.

Ann Pharmacother. 2013 May;47(5):671-85. doi: 10.1345/aph.1R411. Epub 2013 Apr 19. Review.

PMID:
23606551
14.

Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation.

Lee S, Anglade MW, Pham D, Pisacane R, Kluger J, Coleman CI.

Am J Cardiol. 2012 Sep 15;110(6):845-51. doi: 10.1016/j.amjcard.2012.05.011. Epub 2012 May 30.

PMID:
22651881
15.

Role of new drugs for management of atrial fibrillation.

Hollands JM, Gowan M, Riney JN, Deal EN, Kates AM.

Ann Pharmacother. 2012 Dec;46(12):1656-70. doi: 10.1345/aph.1R155. Epub 2012 Dec 18. Review.

PMID:
23249869
16.

Atrial fibrillation: stroke prevention in older adults.

Quinn GR, Fang MC.

Clin Geriatr Med. 2012 Nov;28(4):617-34. doi: 10.1016/j.cger.2012.08.003. Review.

PMID:
23101573
17.

Novel oral anticoagulants for the prevention of thromboembolism in patients with atrial fibrillation.

Lang NN, Connelly DT.

J R Coll Physicians Edinb. 2013;43(2):151-8. doi: 10.4997/JRCPE.2013.213. Review.

PMID:
23734359
18.

Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.

Agarwal S, Bennett D, Smith DJ.

Am J Cardiovasc Drugs. 2010;10(1):37-48. doi: 10.2165/11318870-000000000-00000.

PMID:
20104933
19.

Gender differences in stroke risk of atrial fibrillation patients on oral anticoagulant treatment.

Poli D, Antonucci E, Grifoni E, Abbate R, Gensini GF, Prisco D.

Thromb Haemost. 2009 May;101(5):938-42.

PMID:
19404548
20.

Pharmacoeconomics of atrial fibrillation and stroke prevention.

Bushnell CD, Matchar DB.

Am J Manag Care. 2004 Apr;10(3 Suppl):S66-71. Review.

Supplemental Content

Support Center